Immunoglobulin vs placebo
Adverse events of any severity or seriousness · children with respiratory syncytial virus infection
Summary of findings table ‐ Immunoglobulins showed no clear difference in adverse events of any severity or seriousness compared with placebo (low certainty).
1 finding from 1 review
- Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection 2023 · Cochrane Headline outcomes onlyRR 1.18 [0.78, 1.78]5 studies · 340 participantsLow